Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Active not recruiting 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

NET 2Endocrine 2

Conditions

Uterine Cervical Neoplasms 2Neuroendocrine Tumors 2Glioblastoma 2Vaginal Neoplasms 1Lymphoma, Follicular 1Endometrial Serous Adenocarcinoma 1Astrocytoma 1

Interventions

lutetium Lu 177 dotatate 21Magnetic Resonance Spectroscopy 10pembrolizumab 9Specimen Handling 7Everolimus 7cabozantinib 6Nivolumab 6lenvatinib 5Capecitabine 5177Lu-octreotide, DOTA(0)-Tyr(3)- 5surufatinib 4olaparib 4amino-acid, glucose, and electrolyte solution 4lanreotide 3atezolizumab 3Temozolomide 3Octreotide 3Lutetium-177 3Ipilimumab 3Injections 3Fluorodeoxyglucose F18 3Cyclophosphamide 3gallium Ga 68 dotatate 2fludarabine phosphate 2fludarabine 2avelumab 2X-Rays 2Radiotherapy 2Phantoms, Imaging 2PM 01183 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neuroendocrine Tumors × 3-aminopyridine-2-carboxaldehyde thiosemicarbazone × 1 year × Clear all
NCT04234568 2026-06-01

Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors

National Cancer Institute (NCI)

Phase 1 Active not recruiting
31 enrolled 16 charts
EndocrineNET

Neuroendocrine Tumors

NCT05724108 2026-05-13

Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors

National Cancer Institute (NCI)

Phase 2 Active not recruiting
94 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡